TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma

Leukemia

Volumn 28, Issue 9, 2014, Pages 1872-1884

  Yang, Z Z ^a   Grote, D M ^a   Xiu, B ^b   Ziesmer, S C ^a   Price Troska, T L ^a   Hodge, L S ^a   Yates, D M ^a   Novak, A J ^a   Ansell, S M ^a  

^a MAYO CLINIC   (United States)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD27 ANTIGEN; CD70 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; RAPAMYCIN; RITUXIMAB; SMAD3 PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; TIM3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER FATIGUE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EXHAUSTION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MEMORY T LYMPHOCYTE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL EXHAUSTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY; UPREGULATION;

ANTIGENS, CD27; ANTIGENS, CD70; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LYMPHOMA, B-CELL; MEMBRANE PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908291596     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.84     Document Type: Article

References (55)

1. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T., et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med. 1998; 187: 1383-1393
2. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD., et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998; 188: 2205-2213
3. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443: 350-354
4. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A., et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. 2007; 179: 1979-1987
5. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W., et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology. 2003; 37: 1189-1198
6. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006; 80: 11398-11403
7. Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, Berical A., et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol. 2008; 82: 3154-3160
8. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009; 114: 1528-1536
9. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114: 1537-1544
10. Klein L, Trautman L, Psarras S, Schnell S, Siermann A, Liblau R., et al. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol. 2003; 33: 806-814
11. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207: 2175-2186
12. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-Tumor immunity. J Exp Med. 2010; 207: 2187-2194
13. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ., et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. 2012; 122: 1271-1282
14. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE., et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003; 170: 33-40
15. van Gisbergen KP, van Olffen RW, van Beek J, van der Sluijs KF, Arens R, Nolte MA., et al. Protective CD8 T cell memory is impaired during chronic CD70-driven costimulation. J Immunol. 2009; 182: 5352-5362
16. Oelke K, Lu Q, Richardson D, Wu A, Deng C, Hanash S., et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 2004; 50: 1850-1860
17. Han BK, White AM, Dao KH, Karp DR, Wakeland EK, Davis LS. Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus. Lupus. 2005; 14: 598-606
18. Lee WW, Yang ZZ, Li G, Weyand CM, Goronzy JJ. Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol. 2007; 179: 2609-2615
19. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009; 229: 216-231
20. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol. 2005; 174: 6212-6219
21. Jiang H, Xiao R, Lian X, Kanekura T, Luo Y, Yin Y., et al. Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol. 2012; 143: 39-44
22. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factorbeta receptor. Immunity. 2006; 25: 441-454
23. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006; 25: 455-471
24. Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Yates NR, Secreto FJ., et al. Soluble and membrane-bound TGF-beta-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PloS One. 2013; 8: e59456
25. Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity. 2009; 31: 145-157
26. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated selfreactivity. Nat Rev Immunol. 2007; 7: 443-453
27. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986; 163: 1037-1050
28. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009; 69: 5522-5530
29. Han SH, Yea SS, Jeon YJ, Yang KH, Kaminski NE. Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells. J Pharmacol Exp Ther. 1998; 287: 1105-1112
30. McKarns SC, Kaminski NE. TGF-beta 1 differentially regulates IL-2 expression and [3H]-Thymidine incorporation in CD3 epsilon mAb- And CD28 mAb-Activated splenocytes and thymocytes. Immunopharmacology. 2000; 48: 101-115
31. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood. 2007; 109: 4368-4375
32. Glass G, Papin JA, Mandell JW. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J Histochem Cytochem. 2009; 57: 899-905
33. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA., et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol. 2006; 176: 7726-7735
34. Sung JL, Lin JT, Gorham JD. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naive CD4+ T cells. Int Immunopharmacol. 2003; 3: 233-245
35. Gunnlaugsdottir B, Maggadottir SM, Ludviksson BR. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naive human T-cells. Int Immunol. 2005; 17: 35-44
36. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J., et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003; 4: 49-54
37. Penaloza-MacMaster P, Ur Rasheed A, Iyer SS, Yagita H, Blazar BR, Ahmed R. Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J Virol. 2011; 85: 6168-6174
38. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN., et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med. 2004; 199: 1595-1605
39. Glouchkova L, Ackermann B, Zibert A, Meisel R, Siepermann M, Janka-Schaub GE., et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol. 2009; 182: 718-725
40. Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G., et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998; 5: 163-175
41. Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-Tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther. 1999; 10: 1095-1103
42. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J., et al. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 2000; 7: 1543-1556
43. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002; 3: 83-90
44. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariame AF. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 2004; 11: 497-507
45. Rowley TF, Al-Shamkhani A. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol. 2004; 172: 6039-6046
46. Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kurthy G, Stitz L., et al. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. J Neurosurg. 2010; 113: 280-285
47. Hishima T, Fukayama M, Hayashi Y, Fujii T, Ooba T, Funata N., et al. CD70 expression in thymic carcinoma. Am J Surg Pathol. 2000; 24: 742-746
48. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A., et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 2002; 62: 2592-2599
49. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW., et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood. 2007; 109: 4810-4815
50. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood. 2007; 110: 2537-2544
51. Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012; 72: 3664-3676
52. Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M., et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005; 65: 5428-5438
53. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J., et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-Time RT-PCR and immunohistochemistry. Eur J Cancer. 2005; 41: 1794-1801
54. De Colvenaer V, Taveirne S, Hamann J, de Bruin AM, De Smedt M, Taghon T., et al. Continuous CD27 triggering in vivo strongly reduces NK cell numbers. Eur J Immunol. 2010; 40: 1107-1117
55. Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM., et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2013; 52: 764-774